DE69619110D1 - Adenovirale vektoren für die gentherapie - Google Patents

Adenovirale vektoren für die gentherapie

Info

Publication number
DE69619110D1
DE69619110D1 DE69619110T DE69619110T DE69619110D1 DE 69619110 D1 DE69619110 D1 DE 69619110D1 DE 69619110 T DE69619110 T DE 69619110T DE 69619110 T DE69619110 T DE 69619110T DE 69619110 D1 DE69619110 D1 DE 69619110D1
Authority
DE
Germany
Prior art keywords
helper
gene therapy
adenoviral vectors
preparations
adenoviruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69619110T
Other languages
English (en)
Other versions
DE69619110T2 (de
Inventor
Frank L Graham
Martina Anton
Michael A Rudnicki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advec Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69619110D1 publication Critical patent/DE69619110D1/de
Publication of DE69619110T2 publication Critical patent/DE69619110T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69619110T 1995-06-07 1996-06-07 Adenovirale vektoren für die gentherapie Expired - Lifetime DE69619110T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/473,168 US5919676A (en) 1993-06-24 1995-06-07 Adenoviral vector system comprising Cre-loxP recombination
PCT/CA1996/000375 WO1996040955A1 (en) 1995-06-07 1996-06-07 Adenovirus vectors for gene therapy

Publications (2)

Publication Number Publication Date
DE69619110D1 true DE69619110D1 (de) 2002-03-21
DE69619110T2 DE69619110T2 (de) 2002-07-18

Family

ID=23878471

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69619110T Expired - Lifetime DE69619110T2 (de) 1995-06-07 1996-06-07 Adenovirale vektoren für die gentherapie

Country Status (8)

Country Link
US (2) US5919676A (de)
EP (1) EP0832267B1 (de)
JP (1) JP3492700B2 (de)
AT (1) ATE213022T1 (de)
AU (1) AU724161B2 (de)
CA (1) CA2220997C (de)
DE (1) DE69619110T2 (de)
WO (1) WO1996040955A1 (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US20020136708A1 (en) * 1993-06-24 2002-09-26 Graham Frank L. System for production of helper dependent adenovirus vectors based on use of endonucleases
US20020146392A1 (en) * 1993-06-24 2002-10-10 Frank L. Graham Helper dependent adenovirus vectors based on site-specific recombinases
US6730507B1 (en) 1993-06-24 2004-05-04 Merck & Co., Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
US7045347B2 (en) 1993-06-24 2006-05-16 Advec, Inc. Helper dependent adenovirus vectors based on integrase family site-specific recombinases
US6379943B1 (en) * 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
US6143557A (en) * 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
NZ312332A (en) 1995-06-07 2000-01-28 Life Technologies Inc Recombinational cloning using engineered recombination sites
US20060110798A1 (en) * 1995-06-07 2006-05-25 Graham Frank L Cells expressing recombinase useful for adenovirus vector production and control of gene expression
US6720140B1 (en) 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US6964861B1 (en) 1998-11-13 2005-11-15 Invitrogen Corporation Enhanced in vitro recombinational cloning of using ribosomal proteins
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
DE69638058D1 (de) * 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
FR2737501B1 (fr) * 1995-07-31 1997-10-24 Transgene Sa Nouveaux virus auxiliaires pour la preparation de vecteurs viraux recombinants
DE19623203A1 (de) * 1995-11-24 1997-05-28 Max Planck Gesellschaft Virusvektor für den Transfer stabiler Episome
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
NZ330553A (en) * 1996-01-05 2001-04-27 Genetic Therapy Inc Recombinase-mediated generation of adenoviral vectors where all adenoviral genes of all regions E1 to E4 and L1 to L5 of the adenoviral genome are eliminated
US6228646B1 (en) * 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
US6630346B1 (en) * 1996-06-20 2003-10-07 Merck & Co., Inc. Gene therapy for obesity
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
ATE449851T1 (de) 1996-10-01 2009-12-15 Geron Corp Menschlicher telomerase reverse transcriptase promoter
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US5994132A (en) * 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
EP0953647B1 (de) * 1996-12-16 2008-05-28 Eisai R&D Management Co., Ltd. Verfahren zur herstellung von retroviralen vektoren für die gentherapie
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US5851808A (en) 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
WO1998039411A1 (en) * 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US7622549B2 (en) * 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US20050013825A1 (en) * 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
US7413864B2 (en) * 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
CA2303768C (en) * 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
EP1025217B1 (de) 1997-10-24 2006-10-04 Invitrogen Corporation Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
US7351578B2 (en) * 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
EP1034266A1 (de) * 1997-11-25 2000-09-13 Princeton University Methode zur herstellung adenoviraler vektoren, entsprechende vektoren und ihre verwendung
DE19807265C2 (de) * 1998-02-20 2000-01-05 Centeon Pharma Gmbh Adenoviraler Transfervektor für den Gentransport einer DNA-Sequenz
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
CN1342206A (zh) * 1998-08-28 2002-03-27 杜克大学 在IVa2,100K和/或preterminal protein序列上有缺失的腺病毒
US6303362B1 (en) 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
WO2000046360A1 (en) * 1999-02-04 2000-08-10 Merck & Co., Inc. Improved helper dependent vector system for gene therapy
JP2004501602A (ja) * 1999-02-18 2004-01-22 メルク　アンド　カンパニー　インコーポレイテッド エンドヌクレアーゼの使用に基づくヘルパー依存アデノウイルスベクターの生産のためのシステム
CA2363924A1 (en) 1999-03-02 2000-09-08 Invitrogen Corporation Compositions and methods for use in recombinational cloning of nucleic acids
WO2000052187A2 (en) 1999-03-05 2000-09-08 Merck & Co., Inc. Enhanced system for construction of adenovirus vectors
US20030215423A1 (en) * 1999-04-01 2003-11-20 Merck & Co., Inc. Gene therapy for obesity
JP2003519464A (ja) * 1999-04-06 2003-06-24 メルク アンド カンパニー インコーポレイテッド 代替の血清型のヘルパー依存型アデノウィルスベクターを使用することにより反復ベクター投与が可能になる
EP2345716B1 (de) * 1999-04-06 2015-01-14 Wisconsin Alumni Research Foundation Rekombinante Influenzaviren für Impfstoffe und Gentherapie
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
EP2210948A3 (de) 1999-12-10 2010-10-06 Life Technologies Corporation Verwendung von mehrfachen Rekombinationsstellen mit einzigartiger Spezifizität beim Rekombinationsklonen
US6867022B1 (en) * 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
US7132277B1 (en) * 2000-01-31 2006-11-07 Merck & Co., Inc. Helper dependent vector system for gene therapy
US6872395B2 (en) 2000-04-14 2005-03-29 Wisconsin Alumni Research Foundation Viruses comprising mutant ion channel protein
CA2408328C (en) * 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
US7244560B2 (en) * 2000-05-21 2007-07-17 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
AU2001280576A1 (en) * 2000-07-18 2002-01-30 Uab Research Foundation Tissue-specific self-inactivating gene therapy vector
US7198924B2 (en) * 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
EP1317560A4 (de) * 2000-09-08 2005-10-05 Gen Hospital Corp Sich selbst neuordnende dna vektoren(18.03.02)
EP2336339A3 (de) 2000-09-25 2011-09-14 The Regents of the University of Michigan Herstellung viraler vektoren
JPWO2002041922A1 (ja) * 2000-11-24 2004-03-25 丸山　弘樹 生体に導入された遺伝子の発現産物の活性を制御する方法
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
WO2002092786A2 (en) * 2001-03-26 2002-11-21 The Board Of Trustees Of The Leland Stanford Junior University A helper dependent adenoviral vector system and methods for using the same
EP1390394A4 (de) * 2001-04-19 2004-05-26 Invitrogen Corp Zusammensetzungen und verfahren zur rekombinationsklonierung von nukleinsäuremolekülen
CA2448505A1 (en) * 2001-05-21 2002-11-28 Invitrogen Corporation Compositions and methods for use in isolation of nucleic acid molecules
WO2003002735A2 (en) * 2001-06-28 2003-01-09 Phenogene Therapeutiques Inc. Methods, vectors, cell lines and kits for selecting nucleic acids having a desired feature
US6838285B2 (en) 2001-09-18 2005-01-04 Becton Dickinson Site specific recombinase based method for producing adenoviral vectors
JP4488290B2 (ja) * 2002-01-24 2010-06-23 ザ・スクリップス・リサーチ・インスティテュート 効率的ターゲティングのためのファイバーシャフト変異
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
ES2290449T3 (es) 2002-04-09 2008-02-16 Sanofi Pasteur Limited Acido nucleico de cea modificado y vectores de expresion.
JP2005536231A (ja) * 2002-05-08 2005-12-02 イントロン，インコーポレーテッド アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型ｒｎａトランススプライシングの使用
US8304233B2 (en) 2002-06-04 2012-11-06 Poetic Genetics, Llc Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same
GB2409681B (en) * 2002-09-27 2007-03-28 Powderject Res Ltd Nucleic acid constructs for gene expression
ATE471387T1 (de) * 2002-10-23 2010-07-15 Virxsys Corp Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle
US20040203133A1 (en) * 2003-01-07 2004-10-14 Anja Ehrhardt Helper dependent adenoviral vector system and methods for using the same
NZ542935A (en) 2003-04-23 2008-08-29 Wisconsin Alumni Res Found Recombinant influenza viruses holding a mutation in a transmembrane protein gene
US20050095615A1 (en) * 2003-06-26 2005-05-05 Welch Peter J. Methods and compositions for detecting promoter activity and expressing fusion proteins
JP4668919B2 (ja) * 2003-10-08 2011-04-13 サノフィ パストゥール インコーポレイテッド 修飾ｃｅａ／ｂ７ベクター
EP2287341B1 (de) 2003-12-01 2013-02-13 Life Technologies Corporation Rekombinationsstellen enthaltende Nukleinsäuremoleküle und Verfahren zur Verwendung davon
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
US20060177933A1 (en) * 2004-01-23 2006-08-10 Madaiah Puttaraju Expression of apoA-1 and variants thereof using spliceosome mediated RNA trans-splicing
US8053232B2 (en) * 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
ES2347340T3 (es) 2004-09-13 2010-10-28 Genzyme Corporation Construcciones multimericas.
DE102004047492B4 (de) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
US7871795B2 (en) 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
WO2006083331A2 (en) * 2004-10-08 2006-08-10 Intronn, Inc Use of rna trans-splicing for antibody gene transfer and antibody polypeptide production
CN101103103A (zh) 2004-11-19 2008-01-09 威斯康星旧生研究基金会 具有串联转录单位的重组流感病毒载体
CA2625262A1 (en) * 2005-10-13 2007-10-04 Bc Cancer Agency Modular genomes for synthetic biology and metabolic engineering
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
EP3459441A1 (de) 2006-02-09 2019-03-27 Genzyme Corporation Langsame intraventikuläre freisetzung
EP2010557B1 (de) 2006-03-31 2014-02-26 Wisconsin Alumni Research Foundation Hochtitrige rekombinante influenzaviren für impfstoffe
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
ES2337973B8 (es) * 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
US9109013B2 (en) 2009-10-26 2015-08-18 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CA2863964C (en) 2012-02-07 2021-10-26 Global Bio Therapeutics Usa, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
EP3030163B1 (de) 2013-08-08 2019-03-20 Global Bio Therapeutics, Inc. Klemmvorrichtung für minimal-invasive eingriffe
ES2739288T3 (es) 2013-09-13 2020-01-30 California Inst Of Techn Recuperación selectiva
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
ES2869284T3 (es) 2015-12-11 2021-10-25 California Inst Of Techn Péptidos de diana para dirigir virus adenoasociados (AAV)
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
CA3060573A1 (en) 2017-04-21 2018-10-25 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy
AU2019346447A1 (en) 2018-09-26 2021-04-29 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
EP3921413A1 (de) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanisierte zelllinie
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
EP4022046A2 (de) 2019-08-27 2022-07-06 Wisconsin Alumni Research Foundation (WARF) Rekombinante influenzaviren mit stabilisiertem ha zur replikation in eiern
WO2021080377A1 (ko) * 2019-10-23 2021-04-29 주식회사 제넨메드 헬퍼 플라스미드 기반 가틀리스 아데노바이러스 생산 시스템
BR112022018442A2 (pt) 2020-03-15 2022-11-22 Proteinea Inc Produção de proteína recombinante em insetos
WO2023017494A1 (en) 2021-08-13 2023-02-16 Triovance Holding Llc A skin substitute composition and methods of producing and using the same
CN114369623B (zh) * 2022-01-12 2023-07-07 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用
CN114410683B (zh) * 2022-01-12 2023-11-28 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的RIM3-RNAi及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4920211A (en) * 1988-01-04 1990-04-24 Vanderbilt University Mutated adenovirus E1A gene for E1A promoter stimulation
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU1648092A (en) * 1992-03-19 1993-10-21 Cancer Research Campaign Technology Limited Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins
EP0669987B1 (de) * 1992-09-25 2008-08-13 Aventis Pharma S.A. Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
DE69434486T2 (de) * 1993-06-24 2006-07-06 Advec Inc. Adenovirus vektoren für gentherapie
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター

Also Published As

Publication number Publication date
EP0832267A1 (de) 1998-04-01
WO1996040955A1 (en) 1996-12-19
EP0832267B1 (de) 2002-02-06
CA2220997C (en) 2007-04-24
JP3492700B2 (ja) 2004-02-03
ATE213022T1 (de) 2002-02-15
DE69619110T2 (de) 2002-07-18
AU5889796A (en) 1996-12-30
CA2220997A1 (en) 1996-12-19
US5919676A (en) 1999-07-06
JPH11506334A (ja) 1999-06-08
US20010041173A1 (en) 2001-11-15
AU724161B2 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
DE69619110T2 (de) Adenovirale vektoren für die gentherapie
BG102612A (en) Complementary adenoviral vector systems and cellular lines
NO982417D0 (no) Vektorer og fremgangsmÕter for genoverf°ring til celler
PT797676E (pt) Vector adenoviral recombinante e metodos de utilizacao
DK0667912T3 (da) Defekte adenovirusvektorer og anvendelse heraf i genterapi
ATE387492T1 (de) Verfahren und zusammensetzung zur konservierung von adenoviren
DE69535103D1 (de) Rekombinanter adenovirus welcher eine chimäre penton-base aufweist
ATE282434T1 (de) Eine zusammensetzung enthaltend eine detergenz und einen ein tumorsuppressorgen kodierenden, adenoviralen vektor
SG165153A1 (en) Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP0710288A4 (de) Adenovirale vektoren für die behandlung der hämophilie
EP0866721A4 (de) Adenovirale zielvektoren
CY1111931T1 (el) Φορεις αδενοϊων για την αγωγη νοσου
MX9705937A (es) Procedimiento de preparacion de genoma de adenovirus recombinantes.
AU3169495A (en) Gene therapy for restenosis using an adenoviral vector
WO2000049168A3 (en) Helper adenovirus / helper-dependent adenovirus vector system based on site-specific recombinase activity
WO2000012741A3 (fr) Systeme d'expression inductible
AU3880900A (en) Surface localized colligin/hsp47 in carcinoma cells
AU1099697A (en) Novel xylanases, genes encoding them, and uses thereof
CA2237059A1 (en) Targeted adenovirus vectors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ADVEC INC., ANCASTER, ONTARIO, CA

8381 Inventor (new situation)

Inventor name: ANTON, MARTINA, 81657 MUENCHEN, DE

Inventor name: GRAHAM, FRANK L., HAMILTON, CA

Inventor name: RUDNICKI, MICHAEL A., OTTAWA, CA